West Pharmaceutical Exits SmartDose 3.5mL Manufacturing
Event summary
- West completed sale of manufacturing/supply rights for SmartDose® 3.5mL On-Body Delivery System on July 1, 2026.
- Transaction included transfer of associated facilities.
- Company retains development/manufacturing rights for all other SmartDose versions including 10mL system.
- West generated $3.07B in net sales during fiscal year 2025.
The big picture
This divestiture reflects West's strategic prioritization of higher-volume drug delivery systems amid increasing demand for large-capacity injectables. The move comes as pharmaceutical manufacturers seek more flexible dosing solutions, particularly for biologics and complex therapies. With $3.07B in annual revenue, West maintains significant scale while streamlining its product portfolio.
What we're watching
- Portfolio Focus
- How West's retention of larger-volume SmartDose systems positions it in the high-capacity injectable market.
- Operational Impact
- The pace at which divested facilities transition under new ownership and potential supply chain disruptions.
- Financial Reallocation
- Whether proceeds from this sale will fund R&D in other SmartDose variants or alternative growth areas.
Related topics